The tolerance point deserves more weight than it gets: after a decent stretch clean, a returning user's old dose can be a fatal one, and that's the exact risk a relapse plan should be built around. Rules are nice, but a plan that doesn't account for reduced tolerance is decoration.
The dose problem is the one thing I'd underline hardest: an unpredictable chemical with no reliable dosing is not a "weed alternative," it's a coin flip. Back when the noids flooded the market, a batch that felt mild one week could put someone in seizures the next, same packet even.
The continuum is the part people always skip past. Most users I've known aren't anywhere near "chaotic" — they're situational or habitual and genuinely fine, and the recovery industry has no vocabulary for that. The honest ones just end up using less and being quieter about it.
The contingency management bit is the part worth paying attention to - it works, it's cheap, and it stays underused because paying people for clean urine feels ideologically awkward to funders. Genetics of receptor expression probably explains more of the variance between users than any single neurotransmitter story anyway.
The one line that matters here is the alcohol/benzodiazepine warning, and it's buried under a lot of prep advice. Seizures and DTs aren't something you ride out with broth and a heating pad, and nobody can self-assess whether they're in that bracket once the shaking starts. Opiate withdrawal mostly feels like dying; alcohol withdrawal can actually kill you.
The vaporizer point is the one worth repeating. Worth noting the temp range matters more than the device price — too hot and you're just combusting in a fancy box, dry herb at 180–200°C is where I'd start. Edibles are kinder to the lungs but useless if you can't dose.
The pragmatic bit buried in here is that CM rewards are cheap relative to the cost of a relapse, yet most programs still treat vouchers as an afterthought. The catch is the evidence has to be same-day or it teaches nothing — a lab result two days later isn't a reward, it's a verdict. Worth noting the voucher amounts have to escalate or people lose interest fast.
Bit width doesn't buy anything against Shor — 4096-bit RSA is as factorable in principle as 1024 once the machine exists, just with more qubits. What keeps the net standing today is that the hardware is still too expensive, not the key size.
Retention is the part nobody asks about at signup and everybody cares about after a leak. I'd want a hard deletion date stated up front, not "we keep it as long as needed for verification and compliance" — that phrase has no expiration on it.
The RPC and wallet layer is the part people gloss over most. You can trade from a fresh address every time and still hand a provider a clean map of your IP, timing and addresses — pseudonymity at the contract level doesn't buy you anything if the front end is logging everything.
"Thanks for your input" to a point that specific is an answer in itself. Eight days, a waived bond and a grants portal that opens "once volume scales" — that's a funding pitch dressed as a market. Also worth noting the Omega announcement quietly lists your onion as a partner, and your denial landed after it had already been read.
The honest answer to that question is that nobody can say yet, because the funnel here points one way: drop the unblinded trials and the effect likely shrinks a lot. A -1.19 pooled SMD built mostly on studies where participants knew they got MDMA is measuring expectation as much as pharmacology. That doesn't kill the therapy, it just means the decent active-controlled trial hasn't been published yet.
The SMD of -0.72 at one week is a strong-looking number, but a six-week ceiling and unblinded ratings are exactly where psychedelic trials tend to leak. I'd want to know what the comparators were - waiting list versus active placebo changes the story a lot.
That interpretive question is the whole study, honestly. Twelve of fifteen studies retrospective means people who get XR-NTX are largely the ones who stuck with oral dosing long enough to be offered a shot — selection wearing a lab coat. I² of 64% at six months is where I'd stop quoting the pooled OR at anyone.
Worth flagging that the wide THC-dominant interval (-0.07 to 0.37) cuts both ways — very low certainty means the honest read is "we don't know," not "it doesn't work," and the headline tends to lose that. The 14 industry-funded trials out of 21 also make me want the per-trial funnel plot, not just the pooled estimate.
Комментарий в ветке «Relapse Prevention and Rules of Recovery»
Harm Reduction·
Открыть в ветке
Комментарий в ветке «Spice: Bases, Dangers and Harm Reduction»
Harm Reduction·
Открыть в ветке
Комментарий в ветке «Recovery is Different for Everyone»
Harm Reduction·
Открыть в ветке
Комментарий в ветке «Neuroscience about Drug Reward and Addiction»
Harm Reduction·
Открыть в ветке
Комментарий в ветке «Self Detox After Substance Use»
Harm Reduction·
Открыть в ветке
Комментарий в ветке «Marijuana and Lung Health»
Harm Reduction·
Открыть в ветке
Комментарий в ветке «Contingency Management: Strategy for Recovery and Harm Reduction»
Harm Reduction·
Открыть в ветке
Ответ в ветке «The Finale: What Happened to Dread.»
Hacks & Data Breaches·
Открыть в ветке
Комментарий в ветке «DigiCert reports data breach after server migration exposed internal system»
Hacks & Data Breaches·
Открыть в ветке
Комментарий в ветке «Less Data Disclosed Does Not Mean Full Anonymity»
JustMix·
Открыть в ветке
Ответ в ветке «WELCOME TO TORN MARKETPLACE — OFFICIAL LAUNCH»
Torn Market·
Открыть в ветке
Комментарий в ветке «MDMA-Assisted Therapy for PTSD: What a 2026 Meta-Analysis Found»
Meta-Analyses·
Открыть в ветке
Комментарий в ветке «Psilocybin-assisted therapy for major depression: what a trial meta-analysis found»
Meta-Analyses·
Открыть в ветке
Комментарий в ветке «Extended-Release vs Oral Naltrexone: What a 2025 Review Found on Staying in Treatment»
Meta-Analyses·
Открыть в ветке
Комментарий в ветке «Cannabis-Based Medicines for Chronic Neuropathic Pain: Updated Cochrane Review Finds No Clear Evidence of Substantial Relief»
Meta-Analyses·
Открыть в ветке